Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L1DR
|
|||
| Former ID |
DIB002932
|
|||
| Drug Name |
Recombinant human iduronate-2-sulfatase
|
|||
| Synonyms |
GC-1111; Recombinant human iduronate-2-sulfatase (Hunter syndrome); Recombinant human iduronate-2-sulfatase (Hunter syndrome), Green Cross
Click to Show/Hide
|
|||
| Indication | Hunter syndrome [ICD-11: 5C56.31; ICD-10: E76.1] | Phase 3 | [1] | |
| Company |
Green Cross Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Iduronate 2-sulfatase (IDS) | Target Info | Modulator | [2] |
| BioCyc | Dermatan sulfate degradation (metazoa) | |||
| KEGG Pathway | Glycosaminoglycan degradation | |||
| Metabolic pathways | ||||
| Lysosome | ||||
| Reactome | HS-GAG degradation | |||
| CS/DS degradation | ||||
| WikiPathways | Glycosaminoglycan metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01645189) Safety and Efficacy of Hunterase. U.S. National Institutes of Health. | |||
| REF 2 | The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014 Jan 13;9(1):e85074. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.